PV Bulletin
PvBulletin
Home /Devices/FDA MDR hub highlights VMSR guidance and quarterly malfunction reporting
DevicesFda

FDA MDR hub highlights VMSR guidance and quarterly malfunction reporting

FDA’s MDR reporting hub highlights final VMSR guidance and the VMSR program page describing quarterly summary malfunction MDR reporting and eligibility conditions—prompting SOP and workflow checks.

PV Impact Brief

Urgency: HighConfidence: medium
Relevant for
Local Safety OfficerRegulatory Intelligence LeadPV Operations LeadMedical Device Vigilance LeadPV Quality LeadQPPV
Processes impacted
Local Affiliate ComplianceICSR SubmissionDevice VigilanceRegulatory Intelligence Monitoring
Action needed

Fda update requires triage for Local Affiliate Compliance, ICSR Submission, Device Vigilance; confirm local obligations and document follow-up actions.

Owner

Local Safety Officer

Review cadence

Immediate triage (within 1 business day), then weekly review until closure.

Evidence and confidence

Confidence: mediumSource update date not verified — confirm on the regulator site before acting

Primary-source confirmation recommended before operational implementation.

Full briefing

What changed

FDA’s MDR reporting hub highlights final VMSR guidance and the VMSR program page describing quarterly summary malfunction MDR reporting and eligibility conditions—prompting SOP and workflow checks.

Why it matters

Potential impact spans Local Affiliate Compliance, ICSR Submission, Device Vigilance, Regulatory Intelligence Monitoring, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Practical implication

Fda update requires triage for Local Affiliate Compliance, ICSR Submission, Device Vigilance; confirm local obligations and document follow-up actions.

#Medical Device Vigilance#ICSR#Country Compliance#FDA#Medical Devices

Related updates for your role

RegulatorsMHRAUnited Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

Regulatory action
Public Notification
Tawon Liar
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Regulatory action
Recall
Shiley Cuffed Fenestrated Adult Tracheostomy Tube · Covidien (Medtronic)
Lot/batch: Z-2261-2026
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →